Question · asked by 1 review
HAART + pegylated liposomal doxorubicin vs HAART alone: Clinical response
- Population
- HIV‐infected adults with severe (T1) Kaposi's sarcoma
- Intervention
- HAART + pegylated liposomal doxorubicin
- Comparison
- HAART alone
- Outcome
- Clinical response
HAART + pegylated liposomal doxorubicin showed no clear difference in clinical response compared with HAART alone (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
HAART + pegylated liposomal doxorubicin vs HAART alone Clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma HAART + pegylated liposomal doxorubicin showed no clear difference in clinical response compared with HAART alone (moderate certainty). Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane Headline outcomes only | RR 9 [0.61, 133.08] | 1 study · 10 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.